Charlene Young | SIU School of Medicine

About me

Charlene works with the Parkinson’s Center and the Dale and Deborah Smith Center for Alzheimer’s Research and Treatment and sees Parkinson’s / Movement Disorders, as well as Memory / Dementia patients. She is certified by the American Nurses Credential Center as a certified Family Nurse Practitioner. She is a member of numerous professional organizations, including the American Academy of Nurse Practitioners.

Gender

Female

Education & training

Positions

Certified Nurse Practitioner

Neurology

Board Certifications

Family Nurse Practitioner

Medical School

Illinois State University

Undergraduate Degree

Illinois State University Bloomington, IL. Masters of Science in Nursing- Family Nurse Practitioner

Download my CV

Research

Research Interests

Parkinson's Disease, Alzheimer's Disease, Adult Neurology

Clinical trials

Trial

Neurology

Roche: An open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease

Active not recruiting

POST GRAD: The purpose of this study is to compare the effects, good or bad, of long term gantenerumab on subjects with prodromal or mild Alzheimer's disease.

Trial

Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

Trial

Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

Trial

Neurology

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Active recruiting

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

Trial

Neurology

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Active recruiting

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

Charlene Young, FNP-BC

About me

Gender

Education & training

Research

Clinical trials

Roche: An open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients